Date: July 28, 2021
Elemer Piros, Managing Director & Senior Research Analyst at Roth Capital Markets, speaks about the expanding psychedelics market.
According to Piros, psychedelic clinic research is in an explosive phase. They are seeing confirmation of previous academic work, but this time done properly, with controls.
"The potential is there to actually revolutionize mental health care - depression, PTSD, anxiety, eating disorders and substance abuse," says Piros. The remission rates are double to triple in comparison to placebo or standard of care. "These kinds of results are unheard of in the history of mental health care."